SOCS2 mediates the cross talk between androgen and growth hormone signaling in prostate cancer

Carcinogenesis

Volumn 35, Issue 1, 2014, Pages 24-33

  Iglesias Gato, Diego ^a   Chuan, Yin Choy ^a   Wikström, Pernilla ^b   Augsten, Sandra ^c   Jiang, Ning ^a,d   Niu, Yuanjie ^d   Seipel, Amanda ^c   Danneman, Daniela ^c   Vermeij, Marcel ^e   Fernandez Perez, Leandro ^f   Jenster, Guido ^e   Egevad, Lars ^c   Norstedt, Gunnar ^c   Flores Morales, Amilcar ^a  

^a University of Copenhagen   (Denmark)

^b UMEÅ UNIVERSITY   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d TIANJIN MEDICAL UNIVERSITY   (China)

^e JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^f UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; JANUS KINASE 2; PROTEIN; SOMATOMEDIN C; SRC PROTEIN; STAT5 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 2; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE METASTASIS; CANCER CELL; CANCER INHIBITION; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MIDDLE AGED; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR INVASION;

ADENOCARCINOMA; AGED; ANDROGENS; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; METRIBOLONE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 84891349432     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt304     Document Type: Article

References (62)

1. Sharifi,N. et al. (2010) An update on androgen deprivation therapy for prostate cancer. Endocr. Relat. Cancer, 17, R305-R315.
2. Yuan,X. et al. (2009) Mechanisms mediating androgen receptor reactivation after castration. Urol. Oncol., 27, 36-41.
3. Takahara,K. et al. (2011) Human prostate cancer xenografts in lit/lit mice exhibit reduced growth and androgen-independent progression. Prostate, 71, 525-537.
4. Wang,Z. et al. (2008) Disruption of growth hormone signaling retards prostate carcinogenesis in the Probasin/TAg rat. Endocrinology, 149, 1366-1376.
5. Wang,Z. et al. (2005) Disruption of growth hormone signaling retards early stages of prostate carcinogenesis in the C3(1)/T antigen mouse. Endocrinology, 146, 5188-5196.
6. Guevara-Aguirre,J. et al. (2011) Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci. Transl. Med., 3, 70ra13.
7. Stattin,P. et al. (2004) High levels of circulating insulin-like growth factor- I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort. J. Clin. Oncol., 22, 3104-3112.
8. Corrêa,L.L. et al. (2009) Prostate cancer and acromegaly. Arq. Bras. Endocrinol. Metabol., 53, 963-968.
9. Ahonen,T.J. et al. (1999) Prolactin is a survival factor for androgen-deprived rat dorsal and lateral prostate epithelium in organ culture. Endocrinology, 140, 5412-5421.
10. Li,H. et al. (2004) Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade. Cancer Res., 64, 4774-4782.
11. Li,H. et al. (2005) Activation of signal transducer and activator of transcription- 5 in prostate cancer predicts early recurrence. Clin. Cancer Res., 11, 5863-5868.
12. Tan,S.H. et al. (2008) Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells. Cancer Res., 68, 236-248.
13. Vidal,O.M. et al. (2007) In vivo transcript profiling and phylogenetic analysis identifies suppressor of cytokine signaling 2 as a direct signal transducer and activator of transcription 5b target in liver. Mol. Endocrinol., 21, 293-311.
14. Greenhalgh,C.J. et al. (2005) SOCS2 negatively regulates growth hormone action in vitro and in vivo. J. Clin. Invest., 115, 397-406.
15. Horvat,S. et al. (2001) Lack of Socs2 expression causes the high-growth phenotype in mice. Genomics, 72, 209-212.
16. Metcalf,D. et al. (2000) Gigantism in mice lacking suppressor of cytokine signalling-2. Nature, 405, 1069-1073.
17. Harris,J. et al. (2006) Socs2 and elf5 mediate prolactin-induced mammary gland development. Mol. Endocrinol., 20, 1177-1187.
18. Bergamin,E. et al. (2006) Structural basis for phosphotyrosine recognition by suppressor of cytokine signaling-3. Structure, 14, 1285-1292.
19. Bullock,A.N. et al. (2006) Crystal structure of the SOCS2-elongin C-elongin B complex defines a prototypical SOCS box ubiquitin ligase. Proc. Natl Acad. Sci. USA, 103, 7637-7642.
20. Hu,J. et al. (2009) SOCS2 influences LPS induced human monocytederived dendritic cell maturation. PLoS One, 4, e7178.
21. Chen,H. et al. (2010) Genome-wide analysis of androgen receptor binding and gene regulation in two CWR22-derived prostate cancer cell lines. Endocr. Relat. Cancer, 17, 857-873.
22. Hendriksen,P.J. et al. (2006) Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res., 66, 5012-5020.
23. Henshall,S.M. et al. (2003) Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res., 63, 4196-4203.
24. Bonaccorsi,L. et al. (2000) Androgen receptor expression in prostate carcinoma cells suppresses alpha6beta4 integrin-mediated invasive phenotype. Endocrinology, 141, 3172-3182.
25. Pang,S.T. et al. (2004) Regulation of matrix metalloproteinase 13 expression by androgen in prostate cancer. Oncol. Rep., 11, 1187-1192.
26. Brinkmann,A.O. et al. (1989) The human androgen receptor: domain structure, genomic organization and regulation of expression. J. Steroid Biochem., 34, 307-310.
27. Chuan,Y.C. et al. (2006) Androgen induction of prostate cancer cell invasion is mediated by ezrin. J. Biol. Chem., 281, 29938-29948.
28. Ma,X. et al. (2005) Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. Cancer Res., 65, 5730-5739.
29. Crnalic,S. et al. (2012) Outcome after surgery for metastatic spinal cord compression in 54 patients with prostate cancer. Acta Orthop., 83, 80-86.
30. Hörnberg,E. et al. (2011) Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One, 6, e19059.
31. Lapointe,J. et al. (2004) Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc. Natl Acad. Sci. USA, 101, 811-816.
32. Taylor,B.S. et al. (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell, 18, 11-22.
33. Weiss-Messer,E. et al. (2004) Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells. Mol. Cell. Endocrinol., 220, 109-123.
34. Bolton,E.C. et al. (2007) Cell- and gene-specific regulation of primary target genes by the androgen receptor. Genes Dev., 21, 2005-2017.
35. Wang,Q. et al. (2009) Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell, 138, 245-256.
36. Paliouras,M. et al. (2008) An AKT activity threshold regulates androgendependent and androgen-independent PSA expression in prostate cancer cell lines. Biol. Chem., 389, 773-780.
37. Gkonos,P.J. et al. (2000) Type 1 vasoactive intestinal peptide receptor expression in PC3/AR cells is evidence of prostate epithelial differentiation. Prostate, 42, 137-144.
38. Chuan,Y.C. et al. (2010) Ezrin mediates c-Myc actions in prostate cancer cell invasion. Oncogene, 29, 1531-1542.
39. Vesterlund,M. et al. (2011) The SOCS2 ubiquitin ligase complex regulates growth hormone receptor levels. PLoS One, 6, e25358.
40. Greenhalgh,C.J. et al. (2002) Growth enhancement in suppressor of cytokine signaling 2 (SOCS-2)-deficient mice is dependent on signal transducer and activator of transcription 5b (STAT5b). Mol. Endocrinol., 16, 1394-1406.
41. Zadjali,F. et al. (2012) SOCS2 deletion protects against hepatic steatosis but worsens insulin resistance in high-fat-diet-fed mice. FASEB J., 26, 3282-3291.
42. Mathews,L.S. et al. (1986) Regulation of insulin-like growth factor I gene expression by growth hormone. Proc. Natl Acad. Sci. USA, 83, 9343-9347.
43. Liu,J.L. et al. (2004) Disruption of growth hormone receptor gene causes diminished pancreatic islet size and increased insulin sensitivity in mice. Am. J. Physiol. Endocrinol. Metab., 287, E405-E413.
44. Iwamura,M. et al. (1993) Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines. Prostate, 22, 243-252.
45. Kimura,G. et al. (1996) Insulin-like growth factor (IGF) system components in human prostatic cancer cell-lines: LNCaP, DU145, and PC-3 cells. Int. J. Urol., 3, 39-46.
46. Oudard,S. (2013) Progress in emerging therapies for advanced prostate cancer. Cancer Treat. Rev., 39, 275-289.
47. Saad,F. (2009) Src as a therapeutic target in men with prostate cancer and bone metastases. BJU Int., 103, 434-440.
48. Drake,J.M. et al. (2012) Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression. Proc. Natl Acad. Sci. USA, 109, 1643-1648.
49. Goffin,V. et al. (1996) Sequence-function relationships within the expanding family of prolactin, growth hormone, placental lactogen, and related proteins in mammals. Endocr. Rev., 17, 385-410.
50. Harris,J. et al. (2006) Socs2 and elf5 mediate prolactin-induced mammary gland development. Mol. Endocrinol., 20, 1177-1187.
51. Wennbo,H. et al. (1997) Transgenic mice overexpressing the prolactin gene develop dramatic enlargement of the prostate gland. Endocrinology, 138, 4410-4415.
52. Chan,J.M. et al. (1998) Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science, 279, 563-566.
53. Berinder,K. et al. (2011) Cancer risk in hyperprolactinemia patients: a population-based cohort study. Eur. J. Endocrinol., 165, 209-215.
54. Wu,Z.S. et al. (2011) Tumor expression of human growth hormone and human prolactin predict a worse survival outcome in patients with mammary or endometrial carcinoma. J. Clin. Endocrinol. Metab., 96, E1619-E1629.
55. Rouet,V. et al. (2010) Local prolactin is a target to prevent expansion of basal/stem cells in prostate tumors. Proc. Natl Acad. Sci. USA, 107, 15199-15204.
56. Chng,K.R. et al. (2012) A transcriptional repressor co-regulatory network governing androgen response in prostate cancers. EMBO J., 31, 2810-2823.
57. Varambally,S. et al. (2005) Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell, 8, 393-406.
58. Varambally,S. et al. (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature, 419, 624-629.
59. Yu,J. et al. (2010) An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell, 17, 443-454.
60. Tsurusaki,T. et al. (1998) Expression profile of prostate-specific antigen messenger RNA assessed by in situ hybridization is a novel prognostic marker for patients with untreated prostate cancer. Clin. Cancer Res., 4, 2187-2194.
61. Schwanhäusser,B. et al. (2011) Global quantification of mammalian gene expression control. Nature, 473, 337-342.
62. Gustavsson,C. et al. (2009) Cocoa butter and safflower oil elicit different effects on hepatic gene expression and lipid metabolism in rats. Lipids, 44, 1011-1027.